European Medicines Agency
Evaluation of Medicines for Human Use

London, 6 March 2008
Doc. Ref: EMEA/HMPC/111536/2007

LIST OF REFERENCES SUPPORTING THE ASSESSMENT REPORT ON:

Echinaceae purpureae herba
***Echinacea purpurea* (L.) Moench**
(purple coneflower herb)

The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Articles marked by asterisk (*) were available to the rapporteur only in the form of abstract.

Baetgen D. (1984) Erfolge in der Keuchhusten – Behandlung mit Echinacin. Therapiewoche 34: 5115-5119.

Baetgen D. (1988) Behandlung der akuten Bronchitis im Kindesalter – Praxisstudie mit einem Immunstimulans aus *Echinacea purpurea*. Pädiatrie 1: 66-70.

Barnes J, Anderson LA, Gibbons S, Phillipson JD. (2005) *Echinacea* species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 57(8):929-954. *

Barrett B. (2003) Medicinal properties of *Echinacea*: a critical review. Phytomedicine 10(1): 66-86.

Barrett B. (2004) Efficacy and safety of *Echinacea* in treating upper respiratory tract infections in children: a randomized controlled trial. J Pediatr. 145(1): 135-136.

Barrett B, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D. (2002) Treatment of the common cold with unrefined *Echinacea*. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 137(12): 939-946.

Barrett B, Vohmann M, Calabrese C. (1999) *Echinacea* for upper respiratory infection. J Fam Pract. 48(8): 628-635.

Bauer R. (2002) New knowledge regarding the effect and effectiveness of *Echinacea purpurea* extracts. Wien Med Wochenschr 152(15-16): 407-411.

Bauer R., Foster S. (1991). Analysis of alkamides and caffeic acid derivatives from Echinacea simulata and E. paradoxa roots. Planta Med. 57: 447–449.

Bauer R, Jurcic K, Puhlmann J, Wagner H. (1988a) Immunologic in vivo and in vitro studies on *Echinacea* extracts. Arzneimittelforschung 38: 276-281.

Bauer R, Khan IA, Wagner H. (1988c) TLC and HPLC Analysis of *Echinacea pallida* and *E. angustifolia* roots. Planta Medica 1988; 54:426-430.

Bauer R, Remiger P, Jurcic K, Wagner H. (1989) Beeinflussung der Phagozytose-Aktivität durch *Echinacea*-Extrakte. Zeitschrift für Phytotherapie 10: 43-48.Bauer R, Remiger P, Wagner H (1988b).

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Echinacea. Comparative TLC and HPLC analysis of herbal drugs from *Echinacea purpurea* , E. pallida and E. angustifolia. Part 3. Dtsch. Apoth. Ztg. 128: 174-180.

Binns SE, Purgina B, Bergeron C, Smith ML, Ball L, Baum BR, Arnason JT. (2000) Light-mediated antifungal activity of *Echinacea* extracts. Planta Medica 66(3): 241-244.

Blumenthal M. (2004) *Echinacea* trial. Altern Ther Health Med. 10(2): 12-14.

Bourne LC; Rice-Evans C (1998) Bioavailability of ferulic acid. Biochemical and biophysical research communications 253: 222-227.

Brinkeborn RM, Shah DV, Degenring FH. (1999) Echinaforce and other *Echinacea* fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial. Phytomedicine 6(1): 1-6.

Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. (1997) *Echinacea*-induced cytokine production by human macrophages. Int J Immunopharmacol. 19(7): 371-379.

Cheminat A, Zawatzky R, Becker H, Bruillard R (1988) Caffeoyl conjugates from *Echinacea* species: atructures and biological activity Phytochemistry 27: 2787-2794.

Chow G, Johns T, Miller SC. (2006) Dietary *Echinacea purpurea* during murine pregnancy: effect on maternal hemopoiesis and fetal growth. Biol Neonate. 89(2): 133-138.

Clifford LJ, Nair MG, Rana J, Dewitt DL. (2002) Bioactivity of alkamides isolated from *Echinacea purpurea* (L.) Moench. Phytomedicine 9(3): 249-253.

Currier NL, Miller SC. (2000) Natural killer cells from aging mice treated with extracts from *Echinacea purpurea* are quantitatively and functionally rejuvenated. Exp Gerontol. 35(5): 627-639.

Dietz B, Heilmann J, Bauer R. (2001) Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of *Echinacea purpurea* tincture. Planta Medica 67: 863-864.

Dorsch W. (1996) Klinische Anwendung von Extrakten aus *Echinacea purpurea* oder *Echinacea pallida*. Zeitschrift für ärztliche Fortbildung 90: 117-122.

Dorsch W, Loew D, Meyer-Buchtela E, Schilcher H. (2002) Kinderdosierungen von Phytopharmaka. Kooperation Phytopharmaka BonnESCOP (2003) European Scientific Cooperative on Phytotherapy monographs on the medicinal uses of plant drugs, Fascicule 6, *Echinacea*e *purpureae* herba (purple coneflower herb).

Firenzuoli F, Gori L. (2004) *Echinacea* for treating colds in children. JAMA 291(11): 1323-1324.

Foster S. (1996) The Purple Coneflowers. American Botanical Council, http://www.herbalgram.org/

Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G. (2000) Pregnancy outcome following gestational exposure to *Echinacea*: a prospective controlled study. Arch Intern Med. 160(20): 3141-3143.

Gan XH, Zhang L, Heber D, Bonavida B. (2003) Mechanism of activation of human peripheral blood NK cells at the single cell level by *Echinacea* water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. Int Immunopharmacol. 3(6): 811-824.

Gertsch J, Schoop R, Kuenzle U, Suter A. (2004) *Echinacea* alkylamides modulate TNF-a gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Letters 577(3): 563-569.

Giancaspro G. (2004): *Echinacea purpurea* Aerial Parts. Pharmacopeial Forum 30: 557-560.

Giles JT, Palat CT 3rd, Chien SH, Chang ZG, Kennedy DT. (2000) Evaluation of *Echinacea* for treatment of the common cold. Pharmacotherapy 20(6): 690-697.

Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. (2003) *Echinacea* and truth in labeling. Arch Intern Med. 163(6): 699-704. *

Goel V, Chang C, Slama JV, Barton R, Bauer R, Gahler R, Basu TK. (2002) Alkylamides of *Echinacea purpurea* stimulate alveolar macrophage function in normal rats. Int Immunopharmacol. 2(2-3): 381-387.

Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, Basu TK. (2004) Efficacy of a standardized *Echinacea* preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 29(1): 75-83.

Goel V, Lovlin R, Chang C, Slama JV, Barton R, Gahler R, Bauer R, Goonewardene L, Basu TK. (2005) A proprietary extract from the *Echinacea* plant (*Echinacea purpurea*) enhances systemic immune response during a common cold. Phytother Res. 19(8): 689-694.

Götte K, Roschke I. (2001) A supportive measure in the treatment of acute infections of the respiratory tract in children with recurring infections of the upper respiratory tract. PÄD Praktische Pädiatrie 7, 95-98 (2001)).

Gotti R, Pomponio R, Bertucci C, Cavrini V. (2002) Simultaneous analysis of the lipophilic and hydrophilic markers of *Echinacea* plant extracts by capillary electrophoresis. Journal of Separation Science 25, 15-17, 1079–1086.

Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. (2004) The effect of *Echinacea* (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 75: 89-100.

Grimm W, Müller HH. (1999) A randomized controlled trial of the effect of fluid extract of *Echinacea purpurea* on the incidence and severity of colds and respiratory infections. Am J Med. 106(2):138-143.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto. Clin Pharmacol Ther. 76(5): 428-440. *

HagerROM 2004: Hagers Handbuch der Drogen und Arzneistoffe, CD-ROM Version 5.1.

Heinen-Kammerer T, Holtmannspotter C, Schnabel S, Motzkat K, Kiencke P, Rychlik R. (2005) Effectiveness of echinacin in therapy of chronic recurrent respiratory disease Gesundheitswesen 67(4): 296-301. *

Hoheisel O, Sandberg M, Bertram S, Bulitta M, Schafer M. (1997) Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. European Journal of Clinical Research 9: 261-268.

Hostettmann K. (2003) History of a plant: the example of *Echinacea.* Forsch Komplementarmed Klass Naturheilkd. 10(Suppl 1): 9-12. *

Huntley A, Coon JT, Ernst E. (2005) The safety of herbal medicinal products derived from *Echinacea* species. Drug Safety 28(5): 387-400. *

Izzo AA, Ernst E. (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61(15): 2163-2175.

Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle HP, Heilmann J. (2000) Transport of Alkamides from *Echinacea* Species through Caco-2 Monolayers1. Planta Medica 68: 469-471.

Kemp DE, Franco KN. (2002) Possible leukopenia associated with long-term use of *Echinacea*. J Am Board Fam Pract. 15(5): 417-419.

Kim L, Wollner D, Anderson P, Brammer D. (2004) *Echinacea* for treating colds in children. JAMA 291(11): 1323.

Kinkel HJ, Plate M, Tullner HU. (1984) Effect of Echinacin ointment in healing of skin lesions. Medizinische Klinik 79; 580-583.

Kommission E (1989) Aufbereitungsmonographie *Echinacea purpurea.* Bundesanzeiger vom 2.3.1989.

Koenig K, Roehr CC. (2006) Does treatment with *Echinacea purpurea* effectively shorten the course of upper respiratory tract infections in children? Arch Dis Child. 91(6): 535-537.

Kreft S. (2005) Cichoric acid content and biomass production of *Echinacea purpurea* plants cultivated in Slovenia. Pharmaceutical Biology 43(8): 662-665.

Le Tourneau M. (2004) *Echinacea* fails to show efficacy in treating colds in a pediatric population. Altern Ther Health Med. 10(1): 16.

Lee AN, Werth VP. (2004) Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol. 140(6): 723-727.

Lenk W. (1989) Acute toxicity of various polysaccharides from *Echinacea purpurea* in the mouse. Zeitschrift für Phytotherapie 10: 49-51.

Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. (2006) *Echinacea* for preventing and treating the common cold. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD000530.pub2.

Lindenmuth GF, Lindenmuth EB. (2000) The efficacy of *Echinacea* compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. J Altern Complement Med. 6(4): 327-334.

Logan JL, Ahmed J. (2003) Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant *Echinacea*. Clin Rheumatol. 22(2): 158-159.

Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohmann-Matthes ML. (1989) Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of *Echinacea purpurea*. J Natl Cancer Inst. 81(9): 669-675.

Maffei Facino R. (1995) Echinacoside and caffeoyl conjugates protect collagen from free radica-induced degradation: a potential use of *Echinacea* extracts in the prevention of skin photocamage. Planta Medica 61: 510-514.

Manček B, Kreft S. (2005) Determination of cichoric acid content in dried press juice of purple coneflower (*Echinacea purpurea*) with capillary electrophoresis. Talanta 66(5): 1094-1097.

Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP. (2004) Permeability studies of alkylamides and caffeic acid conjugates from *Echinacea* using a Caco-2 cell monolayer model. J Clin Pharm Ther. 29(1): 7-13.

Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP. (2005a) *Echinacea* alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci. 77(16): 2018-2029.

Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP. (2005b) Cytochrome P450 enzyme-mediated degradation of *Echinacea* alkylamides in human liver microsomes. Chem Biol Interact. 155(1-2): 62-70.

Melchart D, Linde K, Worku F, Bauer R, Wagner H. (1994) Immunomodulation with *Echinacea* – a systematic review of controlled clinical trials Phytomedicine 1: 245-254.

Melchart D, Clemm C, Weber B, Draczynski T, Worku F, Linde K, Weidenhammer W, Wagner H, Saller R. (2002) Polysaccharides isolated from *Echinacea purpurea* herba cell cultures to counteract undesired effects of chemotherapy - a pilot study. Phytother Res.; 16(2):138-142.

Mengs U, Clare CB, Poiley JA. (1991) Toxicity of *Echinacea purpurea* - Acute, subacute and genotoxicity studies. Arzneimittelforschung 41: 1076-1088.

Merali S, Binns S, Paulin-Levasseur M, Ficker C, Smith M, Baum B, Brovelli E, Arnason JT. (2003) Antifungal and Anti-inflammatory Activity of the Genus *Echinacea*. Pharmaceutical Biology (formerly International Journal of Pharmacognosy) 41: 412-420.

Mishima S, Saito K, Maruyama H, Inoue M, Yamashita T, Ishida T, Gu Y. (2004) Antioxidant and immuno-enhancing effects of *Echinacea purpurea*. Biol Pharm Bull. 27(7): 1004-1009.

Mullins RJ. (1998) *Echinacea*-associated anaphylaxis. Med J Aust. 168(4): 170-171. *

Mullins RJ, Heddle R. (2002) Adverse reactions associated with *Echinacea*: the Australian experience. Ann Allergy Asthma Immunol. 88(1): 42-51.

Nordeng H, Havnen GC. (2004) Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Saf. 13(6): 371-380.

Ondrizek RR, Chan PJ, Patton WC, King A. (1999) Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet. 16(2): 87-91.

Orinda D, Diederich J, Wacker A. (1973) Antiviral activity of compounds of *Echinacea purpurea*. Arzneimittelforschung (Drug Research) 23: 1119-1120.

Parnham MJ. (1996) Benefit-risk assessment of the squeezed sap of the pupple coneflower (*Echinacea purpurea*) for long term oral immunostimulation. Phytomedicine 3: 95-102.

Pasco D, Pugh ND, Khan I, Moraes R. (2005) Immunostimulatory agents in botanicals, US patent #20050002962.

Pellati F, Benvenuti S, Magro L, Melegari M, Soragni F. (2004) Analysis of phenolic compounds and radical scavenging activity of *Echinacea* spp. J Pharm Biomed Anal. 35(2): 289-301.

Perri D, Dugoua JJ, Mills E, Koren G. (2006) Safety and efficacy of *Echinacea* (*Echinacea angustafolia, E. purpurea* and *E. pallida*) during pregnancy and lactation. Can J Clin Pharmacol. 13(3): e262-267.

Pietta P, Mauri P, Bauer R. (1998). MEKC Analysis of different *Echinacea* species. Planta Medica 64: 649-652.

Proksch A, Wagner H. (1987) Structural analysis of a 4-O-methylglucuronoarabinoxylan with immunostimulating activity from *Echinacea purpurea* . Phytochemistry 26: 1989-1993.

Pugh ND, Balachandran P, Lata H, Dayan FE, Joshi V, Bedir E, Makino T, Moraes R, Khan I, Pasco DS. (2005) Melanin: dietary mucosal immune modulator from *Echinacea* and other botanical supplements. Int Immunopharmacol. 5(4): 637-647.

Randolph RK, Gellenbeck K, Stonebrook K, Brovelli E, Qian Y, Bankaitis-Davis D, Cheronis J. (2003) Regulation of human immune gene expression as influenced by a commercial blended *Echinacea* product: preliminary studies. Exp. Biol. Med. 228: 1051-1056.

Raner GM, Cornelious S, Moulick K, Wang Y, Mortenson A, Cech NB. (2007) Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem Toxicol. 45(12): 2359-2365. Epub 2007 Jun 15.

Reisch J, Spitzner W, Schulte KE. (1967) The problem of the microbiological activity of simple acetylene compounds. Arzneimittelforschung 17: 816-825.

Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. (2000) Immunopharmacological activity of *Echinacea* preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol. 68(4): 503-510.

Roesler J, Steinmuller C, Kiderlen A, Emmendorffer A, Wagner H, Lohmann-Matthes ML. (1991) Application of purified polysaccharides from cell cultures of the plant *Echinacea purpurea* to mice mediates protection against systemic infections with *Listeria monocytogenes* and *Candida albicans*. Int J Immunopharmacol. 13(1): 27-37.

Schimmer O, Abel G, Behninger C. (1989) Investigations on the genotoxic potency of a neutral polysaccharide from *Echinacea* cell cultures in cultured human lymphocytes. Zeitschrift für Phytotherapie 10: 39-42.

Schulte KE, Rücker G, Boehme R. (1967a) Polyacetilenes as compounds of the roots of burs. Arzneimittelforschung 17: 829-833.

Schulte KE, Rücker G, Perlick J. (1967b) The presence of polyacetylene compounds in *Echinacea purpurea* and *Echinacea angustifolia*. Arzneimittelforschung 17: 825-829.

Schulten B, Bulitta M, Ballering-Bruhl B, Koster U, Schafer M. (2001). "Efficacy of *Echinacea purpurea* in patients with a common cold. A placebo-controlled, randomised, double-blind clinical trial." Arzneimittelforschung 51(7): 563-568.

Schwarz E, Metzler J, Diedrich JP, Freudenstein J, Bode C, Bode JC. (2002) Oral administration of freshly expressed juice of *Echinacea purpurea* herbs fail to stimulate the nonspecific immune response in healthy young men: results of a double-blind, placebo-controlled crossover study. J Immunother. 25(5): 413-420.

Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. (2007) Evaluation of *Echinacea* for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis. 7(7): 473-480. Erratum in: Lancet Infect Dis. 7(9): 580.

Skwarek T, Tynecka Z, Glowniak K, Lutostanska E. (1996) *Echinacea* – inducer of interferons. Herba Polonica 42: 110-117.

Soon SL, Crawford RI. (2001) Recurrent erythema nodosum associated with *Echinacea* herbal therapy. J Am Acad Dermatol. 44(2): 298-299. *

Sperber SJ, Shah LP, Gilbert RD, Ritchey TW, Monto AS. (2004) *Echinacea purpurea* for prevention of experimental rhinovirus colds. Clin Infect Dis. 38(10): 1367-1371.

Steinmuller C, Roesler J, Grottrup E, Franke G, Wagner H, Lohmann-Matthes ML. (1993) Polysaccharides isolated from plant cell cultures of *Echinacea purpurea* enhance the resistance of immunosuppressed mice against systemic infections with *Candida albicans* and *Listeria monocytogenes*. Int J Immunopharmacol. 15(5): 605-614.

Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML. (1984) Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant *Echinacea purpurea*. Infect Immun. 46(3): 845-849.

Stotzem CD, Hungerland U, Mengs U. (1992) Influence of *Echinacea purpurea* on the phagocytosis of human granulocytes. Medical Science Research 20: 719-720.

Taylor JA, Weber W, Calabrese C. (2004) *Echinacea* for treating colds in children. JAMA 291(11): 1324.

Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C. (2003) Efficacy and safety of *Echinacea* in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 290(21): 2824-2830.

Tünnerhoff FK, Schwabe HK. (1956) Studies in human beings and animals on the influence of *Echinacea* extracts on the formation of connective tissue following the implantation of fibrin. Arzneimittelforschung 6: 330-334.

Turner RB, Riker DK, Gangemi JD. (2000) Ineffectiveness of *Echinacea* for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother. 44(6): 1708-1709.

Uang YS; Hsu KY. (1997) A dose-dependent pharmacokinetic study on caffeic acid in rabits after intravenous administration. Biopharmaceutics and drug disposition 18: 727-736.

Vonau B, Chard S, Mandalia S, Wilkinson D, Barton SE. (2001) Does the extract of the plant *Echinacea purpurea* influence the clinical course of recurrent genital herpes? Int J STD AIDS 12(3): 154-158. *

Wacker A, Hilbig W. (1978) Virus-inhibition by *Echinacea purpurea*. Planta Medica 33: 89-102.

Wagner H, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, Stuppner H, Jurcic K, Le Turdu M, Fang JN. (1985) Immunostimulating action of polysaccharides (heteroglycans) from higher plants. Arzneimittelforschung 35(7): 1069-1075.

Wagner H, Stuppner H, Schafer W, Zenk MA. (1988). Immunologically active polysaccharides of *Echinacea purpurea* cell cultures. Phytochemistry 27: 119-126.

Washam C. (2004) *Echinacea* no cure-all for kids. Environ Health Perspect. 112(8): A466.

Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C. (2005) *Echinacea purpurea* for prevention of upper respiratory tract infections in children. J Altern Complement Med. 11(6): 1021-1026.

Westendorf J, Czok G. (1978) Pharmacokinetic of 14C labelled derivatives of cinnamic acid on rats. Zeitschrift für Ernährungswissenschaft 17: 26-36

WHO (1999): WHO monographs on selected medicinal plants, Vol. 1, WHO Geneva 1999, 136-144.

Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, Bauer R. (2005) Bioavailability and pharmacokinetics of alkamides from the roots of *Echinacea angustifolia* in humans. J Clin Pharmacol. 45(6):683-689. *

Yale SH, Liu K. (2004) *Echinacea purpurea* therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med. 2004 164(11): 1237-1241.

Yale SH, Glurich I. (2006) Analysis of the inhibitory potential of *Ginkgo biloba*, *Echinacea purpurea*, and *Serenoa repens* on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med. 11(3): 433-439. *

Zoutewelle G, Van Wijk R. (1990) Effects of *Echinacea purpurea* extracts on fibroblast populated collagen lattice contraction. Phytotherapy Research 4: 77-81.